Serum concentrations of vedolizumab (VDZ) may vary among equally dosed patients which can ultimately affect patient outcomes. Some patients may develop immunogenicity to VDZ by producing antibodies to vedolizumab (ATV) and the presence of persistent anti-vedolizumab antibody has been observed to substantially reduce serum concentrations of vedolizumab. The quantitative measurement of VDZ and ATV levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response.
2.0 mL Serum in a SST Gold Top Tube
2.0 mL Serum from a Red Top Tube in a Plastic Vial
7 days Ambient
9 days Refrigerated
Serum vedolizumab concentration (VDZ) <1.6 ug/ml
Serum concentrations of vedolizumab (VDZ) may vary among equally dosed patients which can ultimately affect patient outcomes. Some patients may develop immunogenicity to VDZ by producing antibodies to vedolizumab (ATV) and the presence of persistent anti-vedolizumab antibody has been observed to substantially reduce serum concentrations of vedolizumab. The quantitative measurement of VDZ and ATV levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response.
Quantitative assay that simultaneously measures serum vedolizumab (VDZ) and antibodies to vedolizumab (ATV) concentrations
3 to 4 days
00913334
80280, 82542